Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia The acquisition of nonsense mutations in the gene encoding the transmembrane granulocyte-colony-stimulating factor receptor, also known as the colony-stimulating factor 3 receptor (CSF3R), is a characteristic feature of patients with severe congenital neutropenia (SCN). 1 Somatic CSF3R gene mutations occur on a background of inherited mutations affecting genes such as ELANE, HAX1 and G6PC3. 2 The incidence of CSF3R mutations dramatically increases when SCN patients progress from chronic neutropenia (30-40%) to acute myeloid leukemia (AML, 80%). 1, 3, 4, 5 Most of the somatic CSF3R mutations that occur in this context truncate the carboxyl terminus from the CSF3R protein (Figure 1 ), which hampers its ability to transduce signals required for neutrophil differentiation. 3 Occasionally, a CSF3R mutation that affects the extracellular domain of the receptor, that is, CSF3R T618I ( Figure 1 , using ENST00000373103 for numbering and C-to-T substitution at nucleotide 1853, exon 14, initially described as T595I), has been detected in transformed SCN 5 and de novo AML. 6 Interestingly, this mutation confers autonomous signaling properties to the receptor, 6 recapitulating the consequences of a germ-line T640N CSF3R mutation (Figure 1 , C-to-A substitution at nucleotide 2088; exon 16, initially described as T617N). This latter mutation was identified in a family with autosomal dominant hereditary neutrophilia, enhanced circulating CD34-positive myeloid progenitors and splenomegaly. 7 Very recently, acquired CSF3R mutations, in most cases T618I, were identified in a majority of patients with chronic neutrophilic leukemia (CNL). 8, 9 Here, we show that CSF3R somatic mutations can be identified in B4% of the patients with chronic myelomonocytic leukemia (CMML). These mutations, which affect distinct residues in CSF3R as compared with SCN, CNL and AML patients, are frequently associated with mutations in ASXL1 gene and have a poor prognostic impact on overall (OS) and AML-free survival in univariate analysis.
The index case of this study was a CMML patient whose sorted monocytes were analyzed by whole exome sequencing, using CD3 þ lymphocytes as control, as part of our ongoing sequencing program in CMML. One of the somatic mutations identified in the leukemic cells of this patient was located in exon 11 (P467S) of CSF3R gene (transcript used for numbering: ENST00000373103, 863 amino acids) and was confirmed by Sanger sequencing. This index case, combined with the recent report of CSF3R mutations in CNL, led us to investigate the frequency of CSF3R mutations in a cohort of 195 additional patients with a diagnosis of CMML according to the WHO criteria (the flowchart is shown in Supplementary Figure 1) . The mutational status of CSF3R gene was first investigated by Sanger sequencing (primers are described in Supplementary Letters to the Editor mutation had been identified by whole exome sequencing, and in exon 13-17, where most of the mutations had been identified in previously studied hematological malignancies ( Figure 1 and Supplementary Table 2 ). Samples were collected in a non-interventional study (MYELOMONO) by the Groupe Francophone des Myelodysplasies. Informed consent was obtained from each patient in accordance with the declaration of Helsinki.
Variants in CSF3R exon 11 and 13-17 were detected in 18 patients. In addition, in 33 cases (17%), an already known A4G variant (rs3918000) was observed in intron 15-16. Using nontumoral DNA from skin fibroblasts or sorted CD3-positive blood lymphocytes as controls, two variants in exon 17, G683R and E935K, were constitutive variants, whereas the M696T variant (exon 17) observed in three patients was a somatic mutation ( Figure 1a and Supplementary Figure 2) . A mutation that affects the same residue (M696I) has been identified previously in a head and neck carcinoma 10 ( Figure 1 and Supplementary table 2).
Considering the presence of this recurrent mutation in CSF3R exon 17, an additional screening of this exon was conducted in 159 CMML patients seen at the Mayo Clinic. The results showed only one additional CSF3R exon 17 variant (E808K; GoA, coding location 2422, genomic location 36932111), and one low minor allele frequency (0.0421) single-nucleotide polymorphism (SNP) not contained in the coding region (G683R; SNP rs3918001, GoA, genomic location 36939721), but failed to detect any additional M696 mutation. In both the Groupe Francophone des Myelodysplasies and the Mayo Clinic series of CMML patients, we never detected the missense exon 14 mutation T618I observed in the majority of chronic neutrophilic leukemias. 8, 9 The index case variant (P467S) was confirmed to be somatic by sanger analysis of non-tumoral DNA ( Figure 1 and Supplementary  Figure 2 ). Two other variants inducing premature stop codon (E450fs and W547X) were demonstrated to be somatic mutations. These three mutations affect residues localized in the extracellular domain of all the predicted proteins. None had been previously Table 2 ). In the absence of nontumoral DNA, we were not able to determine whether the remaining variants were SNPs or acquired mutations (Figure 1 ). Of note, none of the CSF3R mutations identified in CMML affected the hotspot intracellular domain of the receptor, in which acquired truncated mutations induce constitutive activation of the receptor in patients with SCN 11 or AML. 12 Similarly, we did not detect any extracellular T618I mutation recently described in SCN progressing into AML. 11, 12 We extended our analysis to exon 7-9 of CSF3R gene in 118 CMML patients, and detected three variants, one of them (D320N, rs9398018) being present in 7 patients (5.93%), which is a higher frequency than reported in the 1000-genome databank (1.86%; P ¼ 0.02, z test). We further extended the analysis from exon 3 to exon 6 and from exon 10 to exon 12 in 24 patients in whom no variant had been identified in previously screened exons, and did not detect any additional variant (Supplementary Figure 1) .
We focused our prognostic analyses on the six CSF3R gene variants that had been validated as somatic mutations. The comparison of baseline characteristics such as age, gender, WHO category, karyotype and blood cell counts did not reveal any difference between CSF3R-mutated and wild-type patients (Figure 2a ; detailed characteristics in Supplementary Table 3 ). This cohort had been screened previously for mutations in 20 genes. [13] [14] [15] CSF3R mutations were more frequent in ASXL1-mutated CMML patients (83% versus 34%, P ¼ 0.02), whereas no significant association with other explored gene mutations was observed, including with the most frequently mutated genes TET2 and SRSF2 (Figure 2a ). CSF3R mutations were exclusive from SETBP1 mutations that are also associated to ASXL1 mutations (not shown). Follow-up data were available for all 196 patients (median 26.9 months). In univariate analysis, CSF3R-mutated patients had a significantly inferior OS, with 50% of the patients alive at 1 year compared with 83% in the CSF3R wild-type group (Figure 2b , logrank test P ¼ 0.03). CSF3R-mutated patients had also a shorter AMLfree survival as compared with the others (Figure 2c , P ¼ 0.03). Among the 69 ASXL1-mutated patients, OS was inferior in patients with either SETBP1 or CSF3R mutation (N ¼ 13, 1-year OS: 52.7% (95% confidence interval (CI): 23.4-75.5%)) compared with those with wild-type SETBP1 and CSF3R (N ¼ 56; 1-year OS 74.4% (95% CI: 60.6-84.0%), P ¼ 0.02, log-rank test, Supplementary Figure 3) .
We also explored whether the frequent SNP (A/A-A/G) in intron 15-16 (rs3918000) in 17% of the patients could have any significance. Again, the comparison of baseline characteristics such as age, gender, WHO category, karyotype and blood cell counts did not reveal any difference between patients with this CSF3R-intronic SNP and the others (Supplementary Figure 4A) . The SNP was slightly more frequent in patients with a mutation in TET2 gene (P ¼ 0.03), which was identified in 61% of the patients in the whole cohort, without any identified link with other mutated genes. The presence of this SNP did not affect OS (Supplementary Figure 4B) , nor AMLFS (Supplementary Figure 4C) .
In one of these patients, we sorted CD34 þ progenitor cells according to the following immunophenotypes:
þ (granulomonocyte progenitors). We seeded these different fractions at one cell per well in 96-well plates in minimum essential medium-alpha milieu with 10% fetal bovine serume and recombinant human cytokines as described. 13, 14 After 12 days, we genotyped these single cell-derived colonies by direct sequencing. Mutations in TET2 (Q810X), CSF3R (M696T), SRSF2 (P95L) and JAK2 (V617F) genes could be identified in the colonies derived from HSC, indicating their early occurrence during differentiation. The heterozygous CSF3R mutation appeared before any other studied mutation in the HSC compartment. Mutations in TET2 and SRSF2 accumulated secondarily, preceding the appearance of the JAK2 mutation. Mitotic recombination may explain the loss of CSF3R mutation in some subclones and the mutation of the two alleles in others. As observed previously, a growth advantage to the most mutated cells was observed during differentiation (Supplementary Figure 5) .
Altogether, somatic heterozygous CSF3R mutations were identified in 4% of the patients with CMML and a few additional variants identified in leukemic cells could not be confirmed to be mutations due to the lack of non-tumoral material, suggesting a possibly slightly higher incidence. The variants identified in CMML do not affect the hotspot mutations in the intracytoplasmic domain that inhibit the receptor signaling in SCN, and are distinct from the activating mutations observed in hereditary neutrophilia, 7 AML, 6 and the majority of chronic neutrophilic leukemias. 8, 9 Some of the CSF3R mutations observed in CMML have been identified in solid tumors (Figure 1 and Supplementary Table 2) . Their functional consequences remain to be explored, but, in CMML, these mutations preferentially occur in the context of an ASXL1 gene mutation and could complement mutations in SETBP1 gene 14 to negatively influence the clinical course of the disease on an ASXL1 mutation background. Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL). 1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory 2 and might be associated with a shortened overall survival (OS). 3 We therefore conducted this analysis to identify patients at high risk of early progression after FCR chemoimmunotherapy. The construction of a risk predictor for early relapse utilized the comprehensive set of molecular, genetic, clinical and minimal residual disease (MRD) data that were assessed within the CLL8 trial. This large randomized phase 3 study of the German CLL study group had compared FCR with fludarabine/cyclophosphamide (FC) treatment. Risk features were prospectively determined in CLL8 as described before. 1, 4, 5 In addition, TP53 mutations in exons 2-11 were analyzed by a resequencing chip with confirmatory Sanger sequencing. Risk features in the FCR arm of the CLL8 trial were distributed as expected for a cohort of fit patients requiring firstline treatment (Table 1) . MRD quantification was scheduled only for German and Austrian patients per CLL8 protocol. Mainly because of lacking MRD assessments, the patients with sufficient data for risk classification (n ¼ 139) were a sub-population of the intention-to-treat (n ¼ 408) cohort. However, with the exception of a marginally higher frequency of an unmutated IGHV gene in former cohort (P ¼ 0.02), both patient groups did not differ significantly in any of the 14 baseline features assessed. Compared with previous publications of CLL8 results, 1,4 data were analyzed for this investigation at a more mature median follow-up of 70 months and after 550 patients in the intention-to-treat population (n ¼ 817) had progressed or died. Fisher's exact and log-rank tests, respectively, were used to compare proportions of patients and time-dependent variables between patient cohorts. The two sided significance level was set at 0.05. The construction of the risk score additionally utilized published data on the prognostic significance of TP53 aberrations from other trials. [6] [7] [8] [9] In univariate analyses (Table 1) , both high (X10 À 2 ) and intermediate (o10 À 2 but X10 À 4 ) MRD levels, failure to achieve a complete remission according to iwCLL guidelines, 10 TP53 abnormalities (that is, TP53 mutations and/or deletions), absence of chromosomal deletion 13q, presence of deletion 11q, unmutated IGHV genes, elevated serum levels of thymidine kinase (s-TK) and b 2 -microglobulin (s-b2m), as well as male gender, were all significantly associated with shorter progression free survival (PFS) after FCR. Cox proportional hazard models were fitted in order to assess the independent prognostic significance of those covariates. After stepwise forward selection using data from 121 patients with information on all risk feature available, both high (hazard rate (HR) 29.8, Po0.001) and intermediate MRD levels (HR 3.4, Po0.001), an unmutated IGHV gene (HR 2.5, P ¼ 0.001) and male gender (HR 1.8, P ¼ 0.045) remained significantly associated with short PFS.
We decided to base the novel risk predictor on MRD being the variable most closely associated with short PFS in multivariate analysis. High MRD levels as such described poor risk patients with a median PFS of 11.7 months only, comprising B13% of all patients. Patients with intermediate MRD levels (22% of all patients) progressed after a median of 38 months, thus including patients with both satisfactory and unsatisfactory outcome. We hypothesized that covariates which besides MRD levels independently predicted PFS in multivariate models (IGHV status, gender) might be able to subdivide this heterogeneous patient group. Patients with unmutated IGHV who attained intermediate MRD levels after FCR experienced a median PFS of 32 months compared with 45 months in patients with mutated IGHV gene (Figure 1a , HR 3.2, P ¼ 0.02). In contrast, gender was less potent to predict PFS in intermediate MRD level patients (Figure 1b , median PFS, 37 vs 44 months, HR 0.6, P ¼ 0.30). In summary, based on our data from the CLL8 trial, a short PFS after FCR can be expected in patients who either present with high MRD levels (X10 À 2 ) after therapy, or in those who attain intermediate MRD levels (o 10 À 2 but X10 À 4 ) and carry an unmutated IGHV gene.
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